Full-Time

Global Safety Manager

Updated on 8/23/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

Compensation Overview

CA$104.1k - CA$140.9k/yr

Mississauga, ON, Canada

Hybrid

Hybrid/flexible commuter arrangement.

Bachelor's, Master's

Category
Biology & Biotech (1)
Required Skills
Medical Terminology
Quality Assurance (QA)

Get referred to Amgen

See people who can refer or advise you

Requirements
  • A Master's degree and 3 years of directly related experience, or a Bachelor's degree and 5 years of directly related experience.
  • Experience in the biotechnology or pharmaceutical industry, a clinically based role, or a regulatory agency role.
Responsibilities
  • Support or deputise for the Safety Country Lead in representing the local safety function in interactions with regulatory agencies, Global Patient Safety management, local functions, external health care professionals, and other stakeholders.
  • Supervise defined activities or sub-teams within the affiliate Safety team to ensure compliant and efficient local safety activities.
  • Participate in the exchange of safety information throughout the global organization.
  • Provide support to the Safety Country Lead on specific technical or operational areas and deputise when the lead is absent.
  • Work with the Safety Country Lead or Regional Lead on process-improvement initiatives and implementation of legislative changes.
  • Plan training and development activities for local safety staff and train staff from other affiliates using technical expertise.
  • Participate in global, regional, and country safety meetings to share best practices.
  • Provide input into cross-functional programs to reflect local requirements and the operating environment.
  • Supervise delegated technical or professional activities supporting the local Safety function.
  • Act as a safety subject-matter expert within the affiliate.
  • Conduct managerial or supervisory activities for Safety staff when delegated, or provide specialist technical expertise in defined subject areas.
  • Maintain current knowledge of and compliance with local safety regulations, Global Patient Safety policies, and procedures.
  • Ensure local safety activities are documented and filed or archived in accordance with company policies and procedures.
  • Assist with training local customer-facing staff, contractors, agents, business partners, and distributors on adverse-event reporting obligations.
  • Assist the local Safety team during audits, inspections, and pharmacovigilance interactions with local regulators.
  • Serve as a representative and point of contact for health-authority inspections and internal process audits within the role's remit.
  • Capture, route, translate, and follow up on local adverse events for inclusion in the Global Safety database.
  • Assist with safety screening of local medical literature and submission of reportable adverse-event reports.
  • Assist with planning and disseminating urgent safety communications, DHPCs, and DILs according to company and regulatory requirements.
  • Assist with submission of periodic safety reports for local requirements.
  • Exchange adverse-event information with functional service providers and business partners in accordance with agreements and procedures.
  • Review Global Safety database metrics to monitor local operating performance and reporting compliance.
  • Assist with resolving local issues through corrective and preventive actions and related activities.
  • Maintain local quality-assurance measures supporting data quality and inspection readiness.
  • Assist with safety review of protocols for local interventional, noninterventional, and independently sponsored studies.
  • Assist with review of plans and vendor contracts for local market research studies and patient-support programs.
  • Assist with review of local company-sponsored websites and social-media projects for adverse-event capture and compliance.
  • Assist with tracking dissemination of DHPCs, DILs, and risk-minimization measures.
  • Maintain awareness of prescribing information, investigator brochures, and risk-management plans to support product-safety activities and local reviews or translations.
  • Represent Safety in local medical meetings to discuss product-safety issues.
  • Contribute to responses to internal and external safety questions in collaboration with Regulatory or Medical Information.
  • Assist the Safety Country Lead with safety input to local government-agency data requests supporting market-access or reimbursement applications.
  • Assist with tailoring core risk-management plans and periodic reports to local regulatory requirements.
  • Provide product-safety training to commercial and medical colleagues.
  • Assist with local implementation of risk-minimization activities associated with approved risk-management plans.
  • Build awareness of product-safety issues within the local market or clinical research environment and provide feedback to the Safety Country Lead.
  • Perform other duties related to the position as defined in standard operating procedures or requested by the supervisor.
Desired Qualifications
  • Experience with local Risk Management Plan development and safety databases.
  • Specialist expertise in technical or operational activities or the ability to supervise small teams effectively.
  • Ability to communicate and train other staff effectively on specialist areas.
  • Problem-solving skills.
  • Working knowledge of Amgen policies, procedures, and systems.
  • Understanding of legislation applicable to local safety practices.
  • Computer literacy with thorough knowledge of database use.
  • Knowledge of local data privacy requirements.
  • Understanding of relevant medical and safety terminology.
  • Organizational skills.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $10.1 billion, up 10%, and guidance rose to $39.4 billion.
  • Repatha, Evenity, and Uplizna surged 37%, 38%, and 90% in Q2 2026.
  • Amgen presented Repatha VESALIUS-CV data for ESC August 2026, expanding cardiovascular adoption.

What critics are saying

  • FDA proposed withdrawing Tavneos on April 27, 2026; EMA echoed revocation on June 26.
  • Prolia sales fell 32% in Q2 2026 as biosimilars attack Amgen’s legacy franchise.
  • Harbour BioMed won a June 2026 willful patent verdict; MariTide failure would crush growth.

What makes Amgen unique

  • Amgen’s portfolio spans cardiovascular, bone, immunology, oncology, and biosimilars.
  • MariTide targets monthly or less frequent obesity dosing, unlike weekly GLP-1 rivals.
  • Amgen runs seven research labs plus Hyderabad’s 2027 science and innovation center.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Aug 19th, 2026
Amgen surges 3.5% to $440 as healthcare stocks hit record high on strong Q2 results

Amgen shares jumped 3.5% to $440.08 on Wednesday as healthcare stocks reached record highs. The biotech company reported second-quarter revenue of $10.1 billion, up 10%, whilst GAAP earnings surged 65% to $4.37 per share. Twenty-two of Amgen's medicines posted double-digit sales growth, with seventeen products generating over $1 billion in annualised sales. Six key growth products climbed 26% and now account for nearly 70% of product revenue. The rally came as investors rotated into healthcare following excitement around Merck and Moderna's melanoma breakthrough. However, Amgen now trades at a 19% premium to its fair value estimate of $365.04, putting pressure on execution as some products like Prolia face headwinds.

Yahoo Finance
Aug 14th, 2026
Amgen and Regeneron emerge as GLP-1 investment alternatives beyond Eli Lilly and Novo Nordisk

Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.

PR Newswire
Aug 12th, 2026
Amgen to open new science and innovation centre in Hyderabad's Genome Valley

Amgen announced plans to open a new Science and Innovation Center in Genome Valley, Hyderabad, expected to be operational in 2027. The facility will join Amgen's global Research and Development network of seven research laboratories, expanding the company's scientific capabilities. The center will bring together scientists and technologists across discovery chemistry, drug metabolism and pharmacokinetics, and precision medicine. It will integrate experimental science with data and digital innovation to accelerate the discovery and development of medicines. "The new center in Genome Valley expands the way we integrate experimental science with data and technology across our global research capabilities," said Jay Bradner, executive vice president of Research and Development, Artificial Intelligence and Data at Amgen. The facility will complement Amgen's existing technology and innovation site in Hyderabad.

Yahoo Finance
Aug 9th, 2026
Amgen fair value rises to $372 after Q2 beat sparks analyst target hikes to $450

Amgen's modeled fair value has risen from $352.23 to $371.93 per share following strong Q2 results and updated analyst targets. Several firms, including Scotiabank, TD Cowen, BMO Capital, and Oppenheimer, lifted price targets to around $450, citing earnings revisions and a diversified product portfolio. Bernstein noted a 6.8% revenue beat and 12.5% non-GAAP EPS beat in Q2, with raised full-year guidance driven by portfolio-wide execution. Strength came from products including Repatha, Tezspire, Uplizna, Evenity, and Imdelltra. However, Wells Fargo and Citi maintain cautious stances with Equal Weight and Neutral ratings, suggesting current performance may already be priced in. BofA kept its Underperform rating, describing 2026 as focused on execution ahead of key 2027 readouts.

Yahoo Finance
Aug 5th, 2026
Amgen beats Q2 forecast with $10.05B revenue, raises 2026 outlook despite obesity drug setback

Amgen reported second-quarter revenue of $10.05 billion, up 9% year on year, beating Wall Street expectations. Adjusted earnings reached $6.29 per share, surpassing the $5.62 consensus estimate. The biotech firm raised its full-year 2026 outlook, increasing expected revenue to $38.2 billion-$39.4 billion from $37.0 billion-$38.4 billion. Adjusted earnings guidance rose to $22.30-$23.50 per share. Repatha sales surged 37% to $953 million, whilst Evenity jumped 38% to $714 million. Rare-disease therapy Uplizna saw roughly 90% growth. These gains offset a 32% decline in Prolia sales due to biosimilar competition. Amgen discontinued obesity candidate AMG 513 but continues developing MariTide, with Phase 3 data expected in 2027. The stock trades at $406.17, approximately 14.75% above its estimated fair value.